RCHOP与RCDOP方案治疗DLBCL患者间质性肺炎的比较研究
该回顾性研究纳入836例DLBCL患者,经倾向性评分匹配比较114例RCDOP与114例RCHOP方案患者。RCDOP组间质性肺炎发生率显著高于RCHOP组(28.95% vs 2.60%,P<0.01),且随脂质体阿霉素剂量增加而升高。多因素分析显示疾病分期是独立危险因素。
要点
- RCDOP方案间质性肺炎发生率显著高于RCHOP方案(28.95% vs 2.60%,P<0.01)。
- 脂质体阿霉素剂量从25~30 mg/m²增至35~40 mg/m²,间质性肺炎发生率从17.30%升至38.71%(P<0.05)。
- 治疗前Ann Arbor分期高是预后不良的独立危险因素。
核心结论
- 含脂质体阿霉素的一线方案治疗DLBCL与剂量依赖性间质性肺炎发生率升高相关。
- 应用RCDOP方案治疗DLBCL时需加强对间质性肺炎的预防和监测。
研究设计与样本
- 回顾性研究纳入2013年至2018年瑞金医院血液科收治的836例DLBCL患者。
- 其中114例接受RCDOP方案,按年龄、性别、IPI评分1∶1倾向性评分匹配选出114例RCHOP方案患者作为对照。
主要发现
- RCDOP组间质性肺炎发生率为28.95%,RCHOP组为2.60%,差异有统计学意义(P<0.01)。
- RCDOP方案中脂质体阿霉素剂量自25~30 mg/m²增至35~40 mg/m²,完全缓解率自76.90%增至85.50%(P>0.05),间质性肺炎发生率自17.30%增至38.71%(P<0.05)。
- 多因素回归分析显示,应用RCDOP方案、治疗前Ann Arbor分期高是患者预后不良的独立危险因素。
临床怎么用
- 对接受含脂质体阿霉素方案治疗的DLBCL患者,应加强间质性肺炎的预防和监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To identify the risk factors and clinical features associated with the interstitial pneumonia in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP) or rituximab, cyclophosphamide, liposomal doxorubicin, vincristine and prednisone (RCDOP) regimens. Methods: A retrospective study was conducted in 836 patients with DLBCL admitted to the Department of Hematology at Ruijin Hospital from 2013 to 2018. Among them, 114 patients were treated with RCDOP regimen. Using the method of propensity score matching according to age, gender, IPI score of patients, 114 patients treated with RCHOP regimen were selected as controls. Clinical data, including comorbidities, gender, age, B symptoms, international prognostic index (IPI) score, disease stage, serum lactic dehydrogenase (LDH) and β(2) microglobulin (β(2)-MG) level were collected and the risk factors of interstitial pneumonia were further analyzed. Results: The interstitial pneumonia developed more frequently in RCDOP group than RCHOP group (28.95% vs 2.60%, P<0.01) . As the dose of liposomal doxorubicin elevated from 25-30 mg/m(2) to 35-40 mg/m(2), the incidence of interstitial pneumonia accordingly increased from 17.30% to 38.71% (P<0.05) . By multivariate analysis, disease stage was an independent factor of interstitial pneumonitis. Conclusions: Front line regimens containing liposomal doxorubicin in DLBCL patients link to a higher incidence of dose-dependent interstitial pneumonia. Prevention and surveillance should be emphasized in future studies. 目的: 比较RCHOP和RCDOP方案治疗弥漫大B细胞淋巴瘤(DLBCL)后间质性肺炎的发生情况。 方法: 回顾性分析2013年1月至2018年8月上海交通大学医学院附属瑞金医院血液科收治的DLBCL患者836例,其中接受RCDOP方案者114例,根据年龄、性别、IPI评分等因素1∶1配对,选出114例接受RCHOP方案的患者作为对照组。收集患者的基础疾病状况、性别、年龄、有无B症状、IPI评分、疾病分期、血LDH、血β(2)-微球蛋白等相关临床资料,进一步分析间质性肺炎发生的危险因素。 结果: RCHOP方案和RCDOP方案治疗DLBCL后间质性肺炎的发生率分别为2.60%和28.95%,差异有统计学意义(P<0.01)。RCDOP方案中,随着脂质体阿霉素剂量自25~30 mg/m(2)增加至35~40 mg/m(2),患者的完全缓解率自76.90%增至85.50%(P>0.05),间质性肺炎的发生率也自17.30%增至38.71%(P<0.05)。多因素回归分析显示,应用RCDOP方案、治疗前Ann Arbor分期高是患者预后不良的独立危险因素。 结论: 应用RCDOP方案治疗DLBCL时需加强对间质性肺炎的预防和监测。.
引用
- Meng YN, Wang S, Shi Q, et al. [Interstitial pneumonia in patients with diffuse large B-cell lymphoma receiving RCHOP and RCDOP regimens]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 32023732. doi:10.3760/cma.j.issn.0253-2727.2019.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。